
CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:

X^1 is CR^{5a} or N;

X^2 is CR^{5b} or N;

X^3 is CR^{5c} or N;

X^4 is CR^{5d} or N; provided that zero, 1, or 2 of X^1, X^2, X^3, and X^4 are N;

Z^1 and Z^2 are independently CH_2 or O; provided that at least one of Z^1 and Z^2 is CH_2;

a is zero or 1;

b is zero, 1, or 2;

d is zero, 1, or 2; provided that Z^1 and Z^2 are each CH_2 when a, b, and d are each zero;

Q is phenyl substituted with zero to 1 R^1;

A is oxadiazolyl or pyridinyl substituted with R^{4a};

R^2 is:

(i) $C_{1–4}$ alkyl, $C_{1–5}$ alkoxy, or $–NH(C_{1–6}$ alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{2a}; or

(ii) $C_{3–5}$ cycloalkyl substituted with zero to 3 R^{2b};

~~Q is a cyclic group selected from 3- to 8-membered carbocyclyl, 6- to 10-membered aryl, 4- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein said cyclic group is substituted with zero to 4 R^1;~~

each R^1 is independently hydrogen, halo, cyano, hydroxyl, oxo, $C_{1–6}$ alkyl, $C_{2–6}$ alkenyl, $C_{2–6}$ alkynyl, $C_{1–6}$ alkoxy, $–NH_2$, $–NH(C_{1–6}$ alkyl), $–N(C_{1–6}$ alkyl)$_2$, $–C(O)(C_{1–6}$ alkyl), $–C(O)(C_{3–6}$ cycloalkyl), $–NR^xC(O)R^y$, $–C(O)OR^x$, $–C(O)NR^wR^w$, $–S(O)_2(C_{1–6}$ alkyl),

$-S(O)_2(C_{3-6}$ cycloalkyl), $-NR^xS(O)_2(C_{1-6}$ alkyl), $-NR^xS(O)_2(C_{3-6}$ cycloalkyl), $-S(O)_2NR^zR^z$, $-P(O)R^yR^y$, $-(CH_2)_{0-3}(C_{3-6}$ carbocyclyl), $-O(C_{3-6}$ cycloalkyl), –O(4- to 6-membered heterocyclyl), $-(CH_2)_{0-3}$(4- to 6-membered heterocyclyl), or $-(CH_2)_{0-3}$(5- or 6-membered heteroaryl), wherein each of said alkyl, alkoxy, alkenyl, and alkynyl is substituted with zero to 4 R^{1a} and each of said cycloalkyl, heterocyclyl, and heteroaryl is substituted with zero to 4 R^{1b};

each R^{1a} is independently halo, hydroxyl, $-NR^wR^w$, oxo, cyano, C_{1-3} alkoxy, C_{1-3} haloalkoxy, $-C(O)OR^x$, $-C(O)NR^wR^w$, or $-NR^xC(O)R^y$;

each R^{1b} is independently halo, oxo, cyano, hydroxyl, $-NH_2$, C_{1-6} alkyl, C_{1-6} alkoxy, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl)$_2$, or $-NR^xC(O)(C_{1-6}$ alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{1a};

~~R^2 is:~~

~~(i) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, or $-NR^vR^v$, wherein each of said alkyl, alkenyl, alkynyl, and alkoxy is substituted with zero to 6 R^{2a};~~

~~(ii) C_{3-5} carbocyclyl, C_{6-8} spirobicyclyl, or 4- to 5-membered heterocyclyl, wherein each of said carbocyclyl, spirobicyclyl, and heterocyclyl is substituted with zero to 3 R^{2b}; or~~

~~(iii) $-CH_2(C_{3-6}$ cycloalkyl), $-CH_2$(4- to 6-membered heterocyclyl), $-NR^x(CH_2)_{0-2}(C_{3-6}$ cycloalkyl), $-NR^x(CH_2)_{0-2}(C_{5-8}$ bicycloalkyl), $-NR^x(CH_2)_{0-2}(C_{5-8}$ spirobicyclyl), $-NR^x(CH_2)_{0-2}$(4- to 6-membered heterocyclyl), $-NR^x(CH_2)_{0-2}$(5- to 6-membered heteroaryl), $-NR^x(CH_2)_{0-2}$(phenyl), $-O(CH_2)_{0-2}(C_{3-6}$ cycloalkyl), $-O(CH_2)_{0-2}(C_{5-8}$ bicycloalkyl), $-O(CH_2)_{0-2}(C_{5-8}$ spirobicyclyl), $-O(CH_2)_{0-2}$(4- to 6-membered heterocyclyl), $-O(CH_2)_{0-2}$(5- to 6-membered heteroaryl), or $-O(CH_2)_{0-2}$(phenyl), wherein each of said cycloalkyl, heterocyclyl, bicycloalkyl, spirobicyclyl, aryl, and heteroaryl is substituted with zero to 3 R^{2b};~~

each R^{2a} is independently halo, cyano, hydroxyl, oxo, C_{1-3} haloalkyl, C_{1-3} alkoxy, C_{1-3} haloalkoxy, $-NR^xR^x$, $-C(O)(C_{1-6}$ alkyl), $-C(O)(C_{3-6}$ cycloalkyl), $-NR^xC(O)R^y$, $-C(O)(C_{1-6}$ alkyl), $-C(O)OR^x$, $-C(O)NR^wR^w$, $-S(O)_2R^y$, $-S(O)_2(C_{1-3}$ fluoroalkyl), $-NR^xS(O)_2(C_{1-3}$ alkyl), $-NR^xS(O)_2(C_{3-6}$ cycloalkyl), $-S(O)_2NR^zR^z$, or $-P(O)R^yR^y$;

each R^{2b} is independently halo, cyano, hydroxyl, oxo, C_{1-6} alkyl, C_{1-6} alkoxy, $-NR^xR^x$, $-NR^xC(O)O(C_{1-4}$ alkyl), $-C(O)(C_{1-3}$ alkyl), or $-S(O)_2(C_{1-3}$ alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{2a};


R^{3a} and R^{3b} are independently hydrogen, C_{1-3} alkyl, C_{1-3} haloalkyl, or C_{3-6} cycloalkyl, or

R^{3a} and R^{3b}, taken together with the carbon atom to which they are attached, form a $C_{3–6}$ cycloalkyl;

~~A is:~~

~~(i) cyano;~~

~~(ii) phenyl or a 5- or 10-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S, wherein each of said phenyl and heteroaryl is substituted with zero to 3 R^{4a}; or~~

~~(iii)~~  ~~, or~~ ;

~~each~~ R^{4a} is ~~independently~~ halo, cyano, hydroxyl, $–NH_2$, $C_{1–6}$ alkyl, $C_{2–6}$ alkenyl, $C_{2–6}$ alkynyl, $C_{1–6}$ alkoxy, $–(CH_2)_{0–3}NH(C_{1–6}$ alkyl), $–(CH_2)_{0–2}N(C_{1–6}$ alkyl)$_2$, $–(CH_2)_{0–3}(C_{3–6}$ cycloalkyl), or $–(CH_2)_{0–3}$(4- to 6-membered heterocyclyl), wherein each of said alkyl, alkoxy, alkenyl, and alkynyl is substituted with zero to 6 R^{4d} and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R^{4e};

~~R^{4b} is $C_{1–6}$ alkyl, $–(CH_2)_{0–3}(C_{3–6}$ cycloalkyl), $–(CH_2)_{0–3}$(4- to 6-membered heterocyclyl), or $–(CH_2)_{0–3}$(phenyl), wherein each of said alkyl is substituted with zero to 6 R^{4d} and each of said cycloalkyl, heterocyclyl, and phenyl is substituted with zero to 3 R^{4e};~~

~~each R^{4c} is independently hydrogen, $C_{1–6}$ alkyl, $C_{3–6}$ cycloalkyl, 4- to 6-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl;~~

each R^{4d} is independently halo, hydroxyl, $–NR^xR^x$, oxo, cyano, $C_{1–3}$ alkoxy, or $C_{1–3}$ haloalkoxy;

each R^{4e} is independently halo, oxo, cyano, hydroxyl, $–NH_2$, $C_{1–6}$ alkyl, $C_{1–6}$ alkoxy, $–NH(C_{1–6}$ alkyl), or $–N(C_{1–6}$ alkyl)$_2$, wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{4d};

each of R^{5a}, R^{5b}, R^{5c}, and R^{5d} is independently hydrogen, halo, hydroxy, cyano, $C_{1–6}$ alkyl substituted with zero to 6 R^{5e}, $C_{1–6}$ alkoxy substituted with zero to 6 R^{5e}, $–C(O)OR^x$,

$-C(O)NR^wR^w$, $-S(O)_2R^y$, $-S(O)_2NR^zR^z$, or phenyl substituted with zero to 3 R^{5f};

each of R^{5e} is independently halo, hydroxyl, $-NR^xR^x$, oxo, cyano, C_{1-3} alkoxy, or C_{1-3} haloalkoxy;

each R^{5f} is independently halo, oxo, cyano, hydroxyl, $-NH_2$, C_{1-6} alkyl, C_{1-6} alkoxy, $-NH(C_{1-6}$ alkyl), or $-N(C_{1-6}$ alkyl)$_2$, wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{5e};

~~each R^v is independently hydrogen, C_{1-6} alkyl, or alternatively, two R^v, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered bicyclic or spirocyclic ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S, wherein each ring can be substituted with zero to 6 R^{2a};~~

each R^w is independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or alternatively, two R^w, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S;

each R^x is independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

each R^y is independently C_{1-6} alkyl or C_{3-6} cycloalkyl; and

each R^z is independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or alternatively, two R^z, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S.

2. The compound according to claim 1 or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:

~~Q is a cyclic group selected from 3- to 8-membered carbocyclyl, phenyl, 4- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein said cyclic group is substituted with zero to 3 R^1;~~

each R^1 is independently F, Cl, Br, cyano, hydroxyl, oxo, $-NH_2$, ~~$-NR^xR^x$~~, C_{1-5} alkyl, C_{1-4} alkoxy, $-NR^x(C_{1-4}$ alkyl), $-NR^xC(O)R^y$, $-C(O)(C_{1-4}$ alkyl), $-C(O)OR^x$, $-C(O)NR^wR^w$, $-S(O)_2(C_{1-4}$ alkyl), $-S(O)_2(C_{3-6}$ cycloalkyl), $-NR^xS(O)_2(C_{1-4}$ alkyl), $-NR^xS(O)_2(C_{3-6}$ cycloalkyl), $-S(O)_2NR^zR^z$, $-P(O)R^yR^y$, $-(CH_2)_{0-3}(C_{3-6}$ carbocyclyl), $-O(C_{3-6}$ cycloalkyl), $-O(4-$ to 6-membered heterocyclyl), $-(CH_2)_{0-3}(4-$ to 6-membered heterocyclyl), or $-(CH_2)_{0-3}(5-$ or 6-membered heteroaryl), wherein each of said alkyl

and alkoxy is substituted with zero to 4 R^{1a} and each of said cycloalkyl, heterocyclyl, and heteroaryl is substituted with zero to 3 R^{1b};

each R^{1a} is independently F, Cl, hydroxyl, $-NR^wR^w$, oxo, cyano, C_{1-3} alkoxy, C_{1-3} haloalkoxy, or $-C(O)OH$;

each R^{1b} is independently F, Cl, cyano, hydroxyl, oxo, $-NH_2$, C_{1-4} alkyl, C_{1-4} alkoxy, $-NH(C_{1-4}$ alkyl), $-N(C_{1-4}$ alkyl)$_2$, or $-NR^xC(O)$ (C_{1-6} alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{1a};

~~R^2 is:~~

~~(i) C_{1-4} alkyl, C_{1-5} alkoxy, or $-NR^vR^v$, wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{2a};~~

~~(ii) C_{3-5} carbocyclyl, C_{6-8} spirobicyclyl, or 4- to 5-membered heterocyclyl, wherein each of said carbocyclyl, spirobicyclyl, and heterocyclyl is substituted with zero to 3 R^{2b}; or~~

~~(iii) $-CH_2(C_{3-5}$ cycloalkyl), $-CH_2$(4- to 6-membered heterocyclyl), $-NR^x(CH_2)_{0-2}(C_{3-6}$ cycloalkyl), $-NR^x(CH_2)_{0-2}(C_{6-8}$ spirobicyclyl), $-NR^x(CH_2)_{0-2}$(4- to 6-membered heterocyclyl), $-NR^x(CH_2)_{0-2}$(phenyl), $-O$(4- to 6-membered heterocyclyl), $-O$(phenyl), or $-O$(pyridinyl), wherein each of said cycloalkyl, spirobicyclyl, heterocyclyl, phenyl, and pyridinyl is substituted with zero to 3 R^{2b};~~


each R^{2a} is independently F, Cl, hydroxyl, $-NR^xR^x$, oxo, cyano, C_{1-3} alkoxy, C_{1-3} haloalkoxy, or $-C(O)OH$;


~~each R^{2b} is independently F, Cl, cyano, hydroxyl, C_{1-4} alkyl, C_{1-3} alkoxy, $-NR^xR^x$, $-NR^xC(O)O(C_{1-4}$ alkyl), $-C(O)(C_{1-2}$ alkyl), or $-S(O)_2(C_{1-2}$ alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{2a};~~

~~A is:~~

~~(i) cyano;~~

~~(ii) phenyl or a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S, wherein each of said phenyl and heteroaryl is substituted with zero to 3 R^{4a}; or~~

~~(iii)~~ 



each R^{4a} is independently F, Cl, cyano, hydroxyl, $-NH_2$, C_{1-4} alkyl, C_{1-4} alkoxy, $-(CH_2)_{0-3}NH(C_{1-6}$ alkyl), $-(CH_2)_{0-3}N(C_{1-6}$ alkyl)$_2$, $-(CH_2)_{0-3}(C_{3-6}$ cycloalkyl), or $-(CH_2)_{0-3}$(4- to 6-membered heterocyclyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{4d}; and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R^{4e};

~~R^{4b} is C_{1-4} alkyl, $-(CH_2)_{0-3}(C_{3-6}$ cycloalkyl), $-(CH_2)_{0-3}$(4- to 6-membered heterocyclyl), or $-(CH_2)_{0-3}$(phenyl), wherein each of said alkyl is substituted with zero to 6 R^{4d} and each of said cycloalkyl, heterocyclyl, and phenyl is substituted with zero to 3 R^{4e};~~

each R^{4c} is independently hydrogen, C_{1-3} alkyl, or C_{3-6} cycloalkyl;

each R^{4d} is independently F, Cl, hydroxyl, $-NR^xR^x$, oxo, cyano, C_{1-3} alkoxy, or C_{1-3} fluoroalkoxy;

each R^{4e} is independently F, Cl, oxo, cyano, hydroxyl, $-NH_2$, C_{1-4} alkyl, C_{1-4} alkoxy, or $-NH(C_{1-6}$ alkyl), or $-N(C_{1-6}$ alkyl)$_2$, wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{4d};

each of R^{5a}, R^{5b}, R^{5c}, and R^{5d} is independently hydrogen, F, Cl, hydroxy, cyano, C_{1-3} alkyl substituted with zero to 4 R^{5e}, C_{1-3} alkoxy substituted with zero to 4 R^{5e}, $-C(O)OR^x$, $-C(O)NR^wR^w$, $-S(O)_2R^y$, $-S(O)_2NR^zR^z$, or phenyl substituted with zero to 3 R^{5f};

each R^w is independently hydrogen, C_{1-4} alkyl, or C_{3-6} cycloalkyl; or alternatively, two R^w, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S;

each R^x is independently H, C_{1-4} alkyl, or C_{3-6} cycloalkyl;

R^y is C_{1-4} alkyl or C_{3-6} cycloalkyl; and

each R^z is independently hydrogen, C_{1-4} alkyl, or C_{3-6} cycloalkyl; or alternatively, two R^z, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S.

3. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt

or solvate thereof, wherein:

X^1 is CR^{5a};

X^2 is CR^{5b} or N;

X^3 is CR^{5c} or N;

X^4 is CR^{5d} or N; provided that zero, 1, or 2 of X^2, X^3, and X^4 is N;

Z^1 and Z^2 are independently CH_2 or O; provided that at least one of Z^1 and Z^2 is CH_2;

a is 1;

b is 1;

d is 1;

~~Q is a cyclic group selected from cyclopropyl, spiro[3.3]heptenyl, bicyclo[2.2.2]octanyl, phenyl, azetidinyl, morpholinyl, oxaazaspiro[3.3]heptanyl, piperazinyl, piperidinyl, [1,2,4]triazolo[1,5-a] pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, 1H-pyrazolo[3,4-b] pyridinyl, 2,3-dihydrobenzo[d]oxazolyl, 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl, benzo[d][1,3]dioxolyl, benzo[d]oxazolyl, benzo[d]thiazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-b]pyridazinyl, imidazolyl, indazolyl, indolinyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolo[2,1-f] [1,2,4]triazinyl, quinolinyl, tetrahydropyridinyl, thiazolo[4,5-b]pyridinyl, thiazolo[5,4-b] pyridinyl, thiazolyl, thieno[3,2-b]pyridinyl, and triazolyl, wherein said cyclic group is substituted with zero to 2 R^1;~~

each R^1 is independently hydrogen, F, Cl, Br, cyano, hydroxyl, oxo, $C_{1–4}$ alkyl, $C_{1–2}$ fluoroalkyl, $–CH_2Cl$, $C_{1–4}$ hydroxyalkyl, $–C(CH_3)_2CN$, $–CH(OH)CHF_2$, $–CH_2OCH_3$, $C_{1–4}$ alkoxy, $C_{1–2}$ fluoroalkoxy, $–OCF_2Cl$, $–OC(CH_3)_2CN$, $–C(CH_3)_2OCHF_2$, $–OC(CH_3)_2C(O)NH_2$, –C(O)OH, $–C(O)O(C_{1-2}$ alkyl), $–C(O)NH_2$, –O(cyclopropyl), $–CH_2$(cyclopropyl), $–CH_2$(oxetanyl), $–NHC(O)CH_3$, $–NHS(O)_2CH_3$, $–NHS(O)_2CH(CH_3)_2$, $–NHS(O)_2CF_3$, $–NHS(O)_2$(cyclopropyl), $–S(O)_2CH_3$, $–S(O)_2$(cyclopropyl), $–S(O)_2NH_2$, cyclopropyl, acetamidocyclopropyl, cyanocyclopropyl, difluorocyclobutyl, hydroxycyclopropyl, methoxycyclopropyl, cyclohexenyl, dihydropyranyl, oxetanyl, methyloxetanyl, tetrahydropyranyl, aminooxadiazolyl, pyridinyl, or fluorobicyclo[1.1.1]pentyl;

~~R^2 is:~~

~~(i) $C_{1–4}$ alkyl, $C_{1–5}$ alkoxy, or $–NH(C_{1–6}$ alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{2a};~~

~~(ii) C_{3-5} carbocyclyl, C_{6-8} spirobicyclyl, or 4- to 5-membered heterocyclyl, wherein each of said carbocyclyl, spirobicyclyl, and heterocyclyl is substituted with zero to 3 R^{2b}; or~~

~~(iii) $-CH_2$(C_{3-5} cycloalkyl), $-CH_2$(4- to 6-membered heterocyclyl), $-NR^x(CH_2)_{0-2}$(C_{3-6} cycloalkyl), $-NR^x(CH_2)_{0-2}$(C_{6-8} spirobicyclyl), $-NR^x(CH_2)_{0-2}$(4- to 6-membered heterocyclyl), $-NR^x(CH_2)_{0-2}$(phenyl), $-O$(tetrahydropyranyl), $-O$(phenyl), or $-O$(pyridinyl), wherein each of said cycloalkyl, spirobicyclyl, heterocyclyl, phenyl, and pyridinyl is substituted with zero to 3 R^{2b};~~

each R^{2a} is independently F, cyano, hydroxyl, C_{1-2} alkoxy, or $-NR^xR^x$;

each R^{2b} is independently F, cyano, hydroxyl, C_{1-3} alkyl, C_{1-2} fluoroalkyl, C_{1-3} hydroxyalkyl, C_{1-2} alkoxy, C_{1-2} fluoroalkoxy, $-NR^xR^x$, $-NR^xC(O)O(C_{1-4}$ alkyl), $-C(O)(C_{1-2}$ alkyl), $-C(O)(C_{1-2}$ fluoroalkyl), or $-S(O)_2(C_{1-2}$ alkyl);

one of R^{3a} and R^{3b} is hydrogen and the other of R^{3a} and R^{3b} is hydrogen or $-CH_3$;

~~A is:~~

~~(i) pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 2 R^{4a}; or~~

~~(ii) $-C(O)NH$(cyclopropyl), $-NHS(O)_2CF_3$, $-NHC(O)OCH(CH_3)_2$, or $-NHC(O)NHCH(CH_3)_2$, or $-C(O)NHS(O)_2$(cyclopropyl);~~

~~each~~ R^{4a} is ~~independently~~ cyano, $-CH_3$, $-CH(CH_3)_2$, $-C(CH_3)_3$, $-CHF_2$, $-CF_3$, $-CF_2CH_3$, $-C(CH_3)_2F$, $-C(CH_3)_2OH$, $-C(CH_3)_2CN$, $-OCH_3$, $-C(O)N(CH_3)_2$, $-CH_2$(cyclopropyl), cyclopropyl, fluorocyclopropyl, methylcyclopropyl, cyanocyclopropyl, trifluoromethylcyclopropyl, difluorocyclopropyl, methyloxetanyl, tetrahydropyranyl, or fluorobicyclo[1.1.1]pentyl; and

each of R^{5a}, R^{5b}, R^{5c}, and R^{5d} is hydrogen.

4. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:

X^1 is CH;

X^2 is CH or N;

X^3 is CH or N;

X^4 is CH; provided that zero or 1 or X^2 and X^3 are N;

Z^1 and Z^2 are independently CH_2 or O; provided that at least one of Z^1 and Z^2 is CH_2;

a is 1;

b is 1;

d is 1;

~~Q is a cyclic group selected from cyclopropyl, azetidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazolyl, thiazolyl, triazolyl, morpholinyl, piperazinyl, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, indazolyl, indolinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, 1H-pyrazolo[3,4-b] pyridinyl, 2,3-dihydrobenzo[d]oxazolyl, 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl, benzo[d]dioxolyl, benzo[d]thiazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-b] pyridazinyl, pyrrolo[2,1-f] [1,2,4]triazinyl, thiazolo[4,5-b]pyridinyl, thiazolo[5,4-b] pyridinyl, thieno[3,2-b] pyridinyl, and quinolinyl, wherein said cyclic group is substituted with zero to 2 R^1;~~

each R^1 is independently C_{1-4} alkyl, $-CHF_2$, $-CF_3$, $-CH_2CF_3$, $-CF_2CH_3$, $-CH_2CHF_2$, $-C(CH_3)_2OH$, $-CH_2OCH_3$, $-C(CH_3)_2OCH_3$, $-OCH_3$, $-OCH_2CH_3$, $-OC(CH_3)_2CN$, $-C(CH_3)_2OCHF_2$, $-C(O)OCH_3$, $-C(O)OCH_2CH_3$, $-CH_2$(cyclopropyl), $-S(O)_2CH_3$, $-S(O)_2$(cyclopropyl), =O, difluorocyclobutyl, fluorobicyclo[1.1.1]pentyl, oxetanyl, methyl oxetanyl, pyridinyl tetrahydropyranyl, or cyclopropyl substituted with zero to 1 substituent selected from hydroxyl, $-CH_3$, $-OCH_3$, and $-NHC(O)CH_3$;


~~R^2 is $-CH(CH_3)_2$, $-NHCH_2CH_3$, $-NHCH_2C(CH_3)_3$, -NH(methyl cyclopropyl), -NH(methoxyphenyl), or a cyclic group selected from C_{3-5}-cycloalkyl, azetidinyl, oxetanyl, pyrrolidinyl, and bicyclo[1.1.1]pentyl, each cyclic group substituted with zero to 2 substituents independently selected from F, hydroxyl, cyano, $-CH_3$, $-CHF_2$, $-CF_3$, $-C(CH_3)_2OH$, $-OCH_3$, $-OCH_2CH_3$, $-NH_2$, $-N(CH_3)_2$, $-NHC(O)OC(CH_3)_3$, and $-C(O)CF_3$;~~

R^{3a} is hydrogen or $-CH_3$; and

R^{3b} is hydrogen.~~; and~~

~~A is $-C(O)NH$(cyclopropyl), phenyl, or a 5- or 6-membered heteroaryl selected from oxadiazolyl, oxazolyl, pyrazolyl, pyridinyl, pyrimidinyl, thiadiazolyl, and thiazolyl, wherein each of said phenyl and heteroaryl is substituted with zero to 2 substituents independently selected from cyano, fluorobicyclo[1.1.1]pentyl, C_{1-4}-alkyl, C_{1-3} fluoroalkyl, $-C(CH_3)_2CN$, $-C(CH_3)_2OH$, $-OCH_3$, $-C(O)N(CH_3)_2$, $-CH_2$(cyclopropyl), cyclopropyl, fluorocyclopropyl, difluorocyclopropyl, trifluoromethylcyclopropyl, cyanocyclopropyl, methylcyclopropyl, methyl oxetanyl, and tetrahydropyranyl.~~

5. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, having the structure:



~~6. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:~~

~~Q is phenyl substituted with R^{4a};~~


~~A is oxadiazolyl substituted with R^{4a}; and~~

~~R^2 is:~~


~~(i) C_{1-4} alkyl, C_{1-5} alkoxy, or –NH(C_{1-6} alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{2a}; or~~

~~(ii) C_{3-5} cycloalkyl substituted with zero to 3 R^{2b}.~~

6~~7~~. The compound according to any one of claims 1-2 or a stereoisomer or a salt thereof, having the structure:




7~~8~~. The compound according to any one of claims 1-2 or a stereoisomer or a salt thereof, having the structure:



.

89. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, having the structure:



.

910. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:

~~Q is phenyl substituted with R^{4a};~~


A is ~~oxadiazolyl or~~ pyridinyl substituted with R^{4a}~~; and~~

~~R^2 is:~~

~~(i) C_{1-4} alkyl, C_{1-5} alkoxy, or NH(C_{1-6} alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{2a}; or~~


~~(ii) C_{3-5} cycloalkyl substituted with zero to 3 R^{2b}~~.

1011. The compound according to any one of claims 1-2 or a stereoisomer or a salt thereof, having the structure:



.

11~~12~~. The compound according to any one of claims 1-2 or a stereoisomer or a salt thereof, having the structure:



.

12~~13~~. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 to 11~~12~~ or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof.

13~~14~~. A compound according to any one of claims 1 to 11~~12~~ or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.

14~~15~~. A compound according to any one of claims 1 to 11~~12~~ or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in treating pathological fibrosis, cancer, inflammatory disorders, metabolic, or cholestatic disorders.

15~~16~~. The compound for use according to claim 14~~15~~, wherein the pathological fibrosis is liver fibrosis, renal fibrosis, biliary fibrosis, or pancreatic fibrosis.

16~~17~~. A compound according to any one of claims 1 to 11~~12~~ or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in treating nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC).

17~~18~~. A compound according to any one of claims 1 to 11~~12~~ or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in treating idiopathic pulmonary fibrosis (IPF).